These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8094960)

  • 1. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes.
    Tohgi H; Abe T; Takahashi S; Takahashi J; Nozaki Y; Ueno M; Kikuchi T
    J Neural Transm Park Dis Dement Sect; 1993; 5(1):17-26. PubMed ID: 8094960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
    Tohgi H; Abe T; Takahashi S
    J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease.
    Tohgi H; Abe T; Kikuchi T; Takahashi S; Nozaki Y
    Neurosci Lett; 1991 Oct; 132(1):19-22. PubMed ID: 1787913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
    Chia LG; Cheng FC; Kuo JS
    J Neurol Sci; 1993 Jun; 116(2):125-34. PubMed ID: 8336158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotransmitter levels in cerebrospinal fluid in relation to severity of symptoms and response to medical therapy in Parkinson's disease.
    Ondarza R; Velasco F; Velasco M; Aceves J; Flores G
    Stereotact Funct Neurosurg; 1994; 62(1-4):90-7. PubMed ID: 7631094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms.
    Tohgi H; Abe T; Takahashi S; Takahashi J; Hamato H
    Neurosci Lett; 1993 Feb; 150(1):71-4. PubMed ID: 7682308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
    Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
    Fekete M; Tárczy M; Bihari K; Katona G
    Psychopharmacology (Berl); 1984; 82(1-2):93-4. PubMed ID: 6420835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Age changes in concentrations of monoamines and related substances in the cerebrospinal fluid].
    Takahashi S; Abe T
    No To Shinkei; 1991 Apr; 43(4):331-6. PubMed ID: 1716119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAO and L-dopa treatment of Parkinson's disease.
    Tyce GM; Dousa MK; Muenter MD
    J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.
    Strittmatter M; Hamann GF; Strubel D; Cramer H; Schimrigk K
    J Neural Transm (Vienna); 1996; 103(5):591-602. PubMed ID: 8811504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.
    Engelborghs S; Marescau B; De Deyn PP
    Neurochem Res; 2003 Aug; 28(8):1145-50. PubMed ID: 12834252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
    Olanow CW; Gauger LL; Cedarbaum JM
    Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
    Iwasaki S; Hamaguchi K; Iwasaki A; Takakusagi M; Narabayashi Y
    Eur Neurol; 1990; 30(4):194-9. PubMed ID: 2209672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
    Tohgi H; Abe T; Takahashi S; Takahashi J; Ueno M; Nozaki Y
    Neurosci Lett; 1990 Aug; 116(1-2):194-7. PubMed ID: 2259448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies].
    Friedman A
    Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.